0
0
Read Time:7 Minute, 3 Second
The Research Antibodies and Reagents Market was valued at $4.08 billion in 2023 and is expected to grow to $6.77 billion by 2031. In 2024, the market is projected to reach $4.36 billion, experiencing a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031. This steady growth is being driven by factors such as the increasing need for biomarkers in disease diagnosis and treatment, rising cancer cases, and expanding healthcare infrastructure in developing countries.
The Role of Biomarkers in Targeted Therapies
Biomarkers have become an essential component of modern medicine, particularly in the development of targeted therapies. Biomarkers are measurable indicators of disease severity, providing insights into clinical outcomes for various populations and treatment responses. These markers help in selecting more effective, personalized therapies, and their growing demand is influencing the research antibodies and reagents market.
As personalized medicine gains traction, the need for new biomarker identification has surged. Several factors drive this trend, including the rising prevalence of chronic diseases, an aging global population, and the pursuit of more cost-effective clinical trials. Targeted therapies offer a way to lower overall treatment costs while improving patient outcomes, further encouraging research and development in this area.
Download Sample Report Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5055
Population Aging and the Rise of Chronic Diseases
According to reports from the United Nations and the World Bank, the global population of individuals aged 60 and above increased from 566.9 million in 2013 to 673.6 million in 2018. This number is projected to nearly double by 2050, reaching 1.7 billion. The elderly population, particularly in developing countries, is expected to face an increasing burden of chronic diseases, such as cancer, which will drive the demand for biomarkers and related diagnostic tools.
Cancer, in particular, has seen a rapid increase in incidence rates. In 2012, there were 14.1 million new cancer cases worldwide, and this number grew by approximately 28%, reaching 18.1 million by 2018, according to the Global Cancer Observatory (GLOBOCAN). Looking ahead, the incidence of new cancer cases is projected to nearly double by 2040, reaching 29.5 million. Similarly, cancer-related deaths are on the rise, from 8.2 million in 2012 to 9.6 million in 2018. By 2040, cancer mortality is expected to reach 16.4 million annually.
These alarming statistics underscore the urgent need for more effective cancer treatments, including targeted therapies such as monoclonal antibodies. Research antibodies play a crucial role in the development of these therapies, and the growing demand for targeted cancer treatments is expected to propel the market for research antibodies and reagents.
The Impact of Cancer on Emerging Economies
Cancer’s rising prevalence is not limited to developed regions; emerging economies, particularly in Latin America and parts of Asia, are also witnessing an increase in cancer cases. For example, in 2018, Latin America and the Caribbean saw 1.4 million new cancer cases. This figure is projected to grow by 40%, reaching 1.98 million by 2030, and by 2040, it could reach 2.52 million cases. Similarly, cancer-related deaths in these regions are expected to nearly double by 2040, increasing from 672,758 in 2018 to 1.3 million.
This rise in cancer cases has spurred demand for research into new treatments and therapies, particularly in the realm of monoclonal antibodies and related reagents. As healthcare infrastructure improves in these regions, more resources are being devoted to cancer treatment, further driving demand for research antibodies and reagents.
Growing Healthcare Infrastructure in Developing Regions
Developing countries are increasingly investing in healthcare infrastructure, which is expected to drive growth in the research antibodies and reagents market. Governments in these regions are recognizing the importance of improving healthcare services, and as a result, they are allocating more resources toward healthcare development.
India, for instance, has seen significant growth in its healthcare sector, driven by both public and private investment. According to the Indian Brand Equity Foundation (IBEF), the country is a major global supplier of antiretroviral drugs and boasts an extensive network of hospitals and dispensaries. Similarly, China has made strides in healthcare reform through its 13th Five-Year Plan, launched in 2016, which aimed to improve access to comprehensive care in both urban and rural areas.
In Latin America, Brazil has implemented federal law changes that allow foreign investment in hospitals and clinics. This has opened the door for greater investment in healthcare infrastructure, which is expected to boost demand for research antibodies and reagents in the region.
Advancements in Biomarker Discovery
Recent advancements in biomarker discovery have been pivotal to the growth of the research antibodies and reagents market. For instance, protein array technology, which is based on antibodies, has been utilized for biomarker discovery in autoimmune diseases like lupus. Similarly, antibody-based assays have been employed to identify biomarkers for oral cancer in saliva, opening new avenues for non-invasive cancer diagnostics.
Other innovative approaches to biomarker discovery include whole auto-antibody mapping, which has facilitated biomarker identification in systemic autoimmune diseases. Additionally, advances in immunoassays have enabled researchers to discover blood biomarkers for diseases such as schizophrenia. These developments in biomarker discovery have spurred the adoption of research antibodies, particularly in the field of cancer diagnostics.
Browse in Depth : https://www.meticulousresearch.com/product/research-antibodies-and-reagents-market-5055
The Rising Adoption of Immunohistochemistry
Immunohistochemistry (IHC) has become a widely used technique in biomarker identification and cancer diagnostics. IHC allows researchers to detect specific proteins in tissue samples, aiding in the diagnosis of various diseases. One of the most well-known applications of IHC is in HER2-targeted therapy for breast cancer, where researchers use IHC to identify patients who are most likely to benefit from specific treatments.
As the use of IHC continues to grow, so does the demand for research antibodies and reagents. This trend is expected to provide significant opportunities for market vendors in the coming years.
Market Projections and Growth Drivers
The global research antibodies and reagents market is projected to grow at a CAGR of 6.5%, reaching $6.77 billion by 2031. The increasing prevalence of chronic diseases, advancements in biomarker discovery, and expanding healthcare infrastructure in emerging economies are key drivers of this growth.
Additionally, new technologies, such as multiplex immunoassays and protein array platforms, are expected to further boost the market. These innovations offer more efficient ways to discover and validate biomarkers, enabling researchers to develop targeted therapies that are more effective and less costly than traditional treatments.
Quick Buy: https://www.meticulousresearch.com/Checkout/11998366
Research Antibodies and Reagents Market Report Summary:
| Particular | Details |
| Page No | ~280 |
| Format | |
| Forecast Period | 2024-2031 |
| Base Year | 2023 |
| CAGR | 6.5% |
| Market Size (Value) | $6.77 Billion by 2031 |
| Segments Covered | By Product
By Technology
By Application
By End User
|
| Countries Covered | North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, Switzerland, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, Singapore, Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), and Middle East & Africa |
| Key Companies | Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann La-Roche AG (Switzerland), Agilent Technologies, Inc. (U.S.), Becton, Dickinson and Company (U.S.), PerkinElmer, Inc. (U.S.), GenScript Biotech Corporation (U.S.), Bio-Techne Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Santa Cruz Biotechnology, Inc. (U.S.), BioLegend, Inc. (U.S.), Abcam Plc (U.K.), OriGene Technologies, Inc. (U.S.), and Cell Signaling Technology, Inc. (U.S.) |
About Meticulous Research®
Meticulous Research® is a leading provider of comprehensive market intelligence, offering actionable insights and analysis across various industries. Our reports empower businesses to make informed decisions, drive growth, and remain competitive in a rapidly evolving marketplace.
Contact:
Meticulous Market Research Pvt. Ltd.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
